Monotherapy with the Once Weekly Long-Acting GLP-1 Analog LY2189265 for 12 Weeks in Patients with Type 2 Diabetes: Dose-Dependent Effects on Glycemic Control in a Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Grunberger, George
Chang, Anna
Garcia Soria, Martin Gustavo
Botros, Fady T.
Bsharat, Rebhi
Milicevic, Zvonko
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1094-P
引用
收藏
页码：A300 / A300
页数：1
相关论文
共 50 条
  • [1] Monotherapy with the once-weekly GLP-1 analogue LY2189265 for 12 weeks in patients with type 2 diabetes: dose-dependent effects in a randomised, double-blind, placebo-controlled study
    Grunberger, G.
    Chang, A.
    Garcia Soria, G.
    Botros, F. T.
    Bsharat, R.
    Milicevic, Z.
    DIABETOLOGIA, 2011, 54 : S318 - S318
  • [2] Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
    Grunberger, G.
    Chang, A.
    Garcia Soria, G.
    Botros, F. T.
    Bsharat, R.
    Milicevic, Z.
    DIABETIC MEDICINE, 2012, 29 (10) : 1260 - 1267
  • [3] Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
    Terauchi, Yasuo
    Satoi, Yoichi
    Takeuchi, Masakazu
    Imaoka, Takeshi
    ENDOCRINE JOURNAL, 2014, 61 (10) : 949 - 959
  • [4] Reductions in Glycemia and Weight with Once Weekly Dosing of LY2189265, a Long-Acting Glucagon-Like Peptide 1 (GLP-1) Analog in Patients with Type 2 Diabetes Mellitus
    Barrington, Philip
    Hardy, Thomas A.
    Chien, Jenny Y.
    Showalter, H. D. Hollins
    Schneck, Karen B.
    Cui, Sherry
    Tibaldi, Fabian
    Ellis, Bernice
    DIABETES, 2009, 58 : A42 - A42
  • [5] The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
    Umpierrez, G. E.
    Blevins, T.
    Rosenstock, J.
    Cheng, C.
    Anderson, J. H.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2011, 13 (05): : 418 - 425
  • [6] Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
    Ratner, R. E.
    Rosenstock, J.
    Boka, G.
    DIABETIC MEDICINE, 2010, 27 (09) : 1024 - 1032
  • [7] Reductions in glycaemia and weight with once-weekly dosing of LY2189265, a long-acting glucagon-like peptide 1 (GLP-1) analogue in patients with type 2 diabetes mellitus
    Hardy, T. A.
    Barrington, P.
    Chien, J.
    Showalter, H.
    Schneck, K.
    Cui, S.
    Tibaldi, F.
    Ellis, B.
    DIABETOLOGIA, 2009, 52 : S286 - S286
  • [8] LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with type 2 diabetes
    Trautmann, M
    Chen, CF
    Chappell, J
    Dananberg, J
    Patterson, B
    Klausmann, G
    Kapitza, C
    DIABETES, 2003, 52 : A136 - A136
  • [9] Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial
    Yan, Xiang
    Ma, Jianhua
    Liu, Yan
    Wang, Xuhong
    Li, Sheli
    Yan, Shuang
    Mo, Zhaohui
    Zhu, Yikun
    Lin, Jingna
    Liu, Jie
    Jia, Ying
    Liu, Li
    Ding, Ke
    Xu, Michael
    Zhou, Zhiguang
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [10] LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with Type 2 diabetes.
    Trautmann, ME
    Chen, CF
    Chappell, JC
    Dananberg, J
    Patterson, B
    Klausmann, G
    Kapitza, C
    DIABETOLOGIA, 2003, 46 : A63 - A63
12345